Demonstration Formulary
4 Central nervous system
PALLIATIVE CARE PHYSICIANS - Guidelines for the use of drugs in symptom control
04-08-01 Lacosamide
| Lacosamide |
|
Formulary
|
Tablets Syrup Supported by an ESCA |
 ESCA: Lacosamide |
|
Links
- Administration of depot antipsychotic injections during COVID-19 in stable adult patients
- ESCA: Eslicarbazepine
- ESCA: Lacosamide
- ESCA: Lacosamide
- ESCA: Lacosamide
- ESCA: Perampanel
- ESCA: Perampanel
- ESCA: Rufinamide
- ESCA: Rufinamide
- ESCA: Vigabatrin
- ESCA: Zonisamide
GlaxoSmithKline: Advance notification of Retigabine (Trobalt) discontinuation- Guidance Document on Valproate Use in Women and Girls of Childbearing Years (March 2019)
- Guidance Document on Valproate Use in Women and Girls of Childbearing Years (March 2019)
- Medicines related to valproate: risk of abnormal pregnancy outcomes
- Medicines related to valproate: risk of abnormal pregnancy outcomes
- MHRA : Valproate use in women and girls (August 2018)
- MHRA safety update on pigmentation July 2013
- MHRA: Letters sent to healthcare professionals in September 2016, including retigabine withdrawal
- MHRA: Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19) pandemic
- MHRA: Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19) pandemic
- MHRA: Valproate use in women and girls (August 2018)
- MHRA: Valproate use in women and girls (August 2018)
- MHRA: Valproate use in women and girls (August 2018)
- MHRA: Valproate use in women and girls (August 2018)
- NHS England: (Schedule 3 Controlled Drugs) Patient Leaflet; Are you taking gabapentin or pregabalin? (Lyrica, Alzain, Neurontin)
- NHS England: (Schedule 3 Controlled Drugs) Patient Leaflet; Are you taking gabapentin or pregabalin? (Lyrica, Alzain, Neurontin)
- NHS England: (Schedule 3 Controlled Drugs) Patient Leaflet; Are you taking gabapentin or pregabalin? (Lyrica, Alzain, Neurontin)
- NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137 The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
- NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
- NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
- NICE TA753: Cenobamate for treating focal onset seizures in epilepsy
UKMI Q&A: Anti-depressant use in epileptics: Choice of agent?- UKMI Q&A: Anti-epileptics increasing the risk of osteoporosis?
- UKMI Q&A: Gabapentin and pregabalin - are they safe whilst breast feeding?
- UKMI Q&A: Information on change of phenytoin capsules to tablets and vice versa
- UKMI Q&A: Why is there a limit on the dose and duration of use for carbamazepine suppositories?
- UKMI: The Use of Generic Anti‐Epileptics Drugs in Patients with Epilepsy
- Valproate form: Annual Risk Acknowledgement form (March 2019)
- Valproate form: Annual Risk Acknowledgement form (March 2019)
- Women of childbearing potential: Educational Risk Minimisation Materials
- Women of childbearing potential: Educational Risk Minimisation Materials